ClinicalTrials.gg
RecruitingNCT04765098Updated Nov 4, 2026

Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

A Phase 2 interventional study of Tamoxifen and Etoposide in Glioblastoma Multiforme, sponsored by AHS Cancer Control Alberta. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by AHS Cancer Control Alberta · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Glioblastoma with a site in Canada — 17 open to participants now, 34 under way, 5 of them phase 3. Glioblastoma · Canada.

Planned enrollment
61st of 111
60 · median 74
Started
2022
with 6 others
Phase 2
33 of 118
6 open now
Primary completion
2026-12
later than 14 of 33 live
Registered
93rd of 118
by date
Lead sponsor
7 of 118
AHS Cancer Control Alberta

Among the 118 studies in Glioblastoma with a site in Canada, this one is the 61st largest by planned enrollment of the 111 interventional ones that give a count, is one of 7 that started in 2022, is one of 33 in phase 2, reaches primary completion later than 14 of the 33 other live ones, and was the 93rd registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

17 of the 118 studies in Glioblastoma with a site in Canada are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Glioblastoma with a site in Canada, or all of them as a file.
02

Study summary

The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.

03

Conditions studied

  • Glioblastoma Multiforme

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. proven GBM with progression after previous chemoradiotherapy with temozolomide.
  2. Progression documented by MRI with at least one bi-dimensionally measurable target lesion with one diameter of at least 10 mm, visible on two or more axial slices 5 mm apart.
  3. Not received radiotherapy within the three months before the diagnosis of progression.
  4. Stable or decreasing dose of prior to randomization: corticosteroids (dexamethasone) should be given at the lowest dose needed to control symptoms arising from increased intracerebral edema.
  5. performance 0-2 (Appendix 2).
  6. Age from 18-65 years.
  7. Women of child bearing potential () must have a negative serum (or urine) pregnancy test within 72 hours prior to the first dose of study treatment. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not . Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes.
  8. Patients of childbearing / should use adequate methods, as defined by the investigator, during the study treatment period and for a period of 60 days after the last dose of study drug. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.

    Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.

  9. Laboratory evaluation obtained within 7 days prior to randomization, with adequate function as defined below:

    • ≥ 1.5 x 109/L
    • ≥ 100 x 109/L
    • Serum creatinine ≤ 1.5 times
    • Total serum ≤ 1.5 times ULN
    • \< 3 times ULN
    • AST \< 3 times ULN
    • Alkaline phosphatase \< 3 times ULN
  10. Patient must understand and sign an prior to study registration.

Exclusion criteria

Exclusion Criteria:

  1. History of another or a concurrent malignancy (exceptions include patients who have been disease-free for 3 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ.
  2. Uncontrolled hypertension (systolic blood pressure >150 mm Hg or diastolic blood pressure >100 mm Hg).
  3. Any arterial or venous thrombosis up to 6 months before registration.
  4. Evidence of recent hemorrhage on brain MRI.
  5. Substantial cardiovascular disease: cerebral vascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina, congestive heart failure (> Classification Class II), or serious cardiac arrhythmia requiring medication.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Etoposide

    Drug: Etoposide

  • Experimental
    Tamoxifen

    Drug: Tamoxifen

Interventions

  • Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously

  • etoposide 50mg/m2 daily

06

What researchers measure

Primary outcomes

  1. 3 month progression-free survival

    Time between randomization and radiographic or clinical progression leading to change in therapy for recurrent disease or death due to any cause.

    Time frame: 3 months

Secondary outcomes

  1. One-year progression-free survival

    Time between randomization and radiographic or clinical progression leading to change in therapy for recurrent disease or death due to any cause.

    Time frame: 12 months

  2. Overall survival

    Time between randomization and death due to any cause. Patients without an event will be censored the last time they were known to be alive.

    Time frame: Median, 6-month, 1-year, and 2-year OS rates will be measured

  3. Health-related quality-of-life status

    Health-related quality-of-life will be assessed using the EORTC QLQ-BN20 brain tumor module questionnaire. This is a self-report questionnaire consisting of 20 items that assess future uncertainty, visual disorder, motor dysfunction, and communication deficit in brain tumor patients

    Time frame: Throughout study completion, up to 5 years.

  4. Adverse events

    This includes fatigue, hematologic toxicities (neutropenia, thrombocytopenia, leukopenia, anemia), liver toxicities, hypertension, diarrhea, seizures and thrombosis and will all be recorded.

    Time frame: Throughout the whole duration of the trial, up to 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Dec 2026, 59 months after the start.

Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 59 months is close to that.

Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2021
First posted
Feb 21, 2021
StartActual
Jan 28, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Jul 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04765098
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Jan 28, 2022
Primary completion
Dec 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Jacob Easaw, MD, PhD, FRCPC
Contact
jay.easaw@ahs.ca
780-432-8290

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamoxifen

Start the discussion